Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Starpharma.
RELATED STOCKHEAD STORIES
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 3
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Gains in Gold and Tech stocks offset by losses in Energy as oil price retreats
Health & Biotech
ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc
Health & Biotech
ASX Health Stocks: Starpharma says Viraleze reduces viral load in nose, effective in Covid-19
Health & Biotech
ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial
Health & Biotech
“Market is going to be surprised” as Firebrick Pharma set to launch antiviral nasal spray, Nasodine
Health & Biotech
ASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 study
Health & Biotech
ASX Health Stocks: Starpharma full steam ahead on VIRALEZE study, Dimerix to use QYTOVRA as brand name
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Tempus Trap, ASX200 loses its bottle, James Bay makes more hay on 2nd day
News
In Case You Missed It: A consumer products divestment and a dash of lithium
News
ASX Small Caps Lunch Wrap: Who else is up to something totally pointless today?
Health & Biotech
ASX Health Stocks: Starpharma jumps 30pc after cancer drug helps enable ‘100 per cent’ control rate
News
Top 10 at 11: Starpharma has excellent drug trial news, Firebrick doesn’t and NIS takes a breather
News
Market Highlights: ASX to fall as Big Tech retreats; and here’s how Aussies are being duped by scammers
Health & Biotech